Ee Wee - Haw Par CEO
HAWPF Stock | USD 7.12 0.29 3.91% |
CEO
Mr. Wee Ee Lim is President, Chief Executive Officer, Executive Director of Haw Par Corporation Ltd. He joined the Group in 1986 and became President CEO of Haw Par Corporation Limited in 2003. He was appointed to the Board on 23 March 1994 and was last reelected on 28 April 2015. Mr Wee is a member of the Investment Committee. He was closely involved in the management and growth of the Group over the last 30 years. He is a Director and Deputy Chairman of UOL Group Limited. He is a Director of United Industrial Corporation Limited and Wee Foundation. He was previously a Director of Pan Pacific Hotels Group Limited, Singapore Land Limited and Hua Han Health Industry Holdings Limited . He holds a Bachelor of Arts degree from Clark University, USA. since 2003.
Age | 62 |
Tenure | 21 years |
Phone | 65 6337 9102 |
Web | https://www.hawpar.com |
Haw Par Management Efficiency
Haw Par's management efficiency ratios could be used to measure how well Haw Par manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | CEO Age | ||
Michael Heuer | Roche Holding | 64 | |
Michael Ball | Novartis AG ADR | 62 | |
Chris Ilsley | Novartis AG ADR | N/A | |
William Anderson | Roche Holding | 57 | |
Bruno Strigini | Novartis AG ADR | N/A | |
Pascal Soriot | AstraZeneca PLC ADR | 60 | |
Jacob Naarden | Eli Lilly And | 39 | |
Joseph Jimenez | Novartis AG ADR | 58 | |
Elizabeth Barrett | Novartis AG ADR | 56 | |
Paul Hudson | Novartis AG ADR | 51 | |
Richard Saynor | Novartis AG ADR | 57 | |
Severin Schwan | Roche Holding | 56 | |
Osamu Nagayama | Roche Holding | 69 | |
Francesco Balestrieri | Novartis AG ADR | N/A | |
PerOlof Attinger | Roche Holding | 58 |
Management Performance
Return On Equity | 0.0424 | |||
Return On Asset | 0.0063 |
Haw Par Leadership Team
Elected by the shareholders, the Haw Par's board of directors comprises two types of representatives: Haw Par inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haw. The board's role is to monitor Haw Par's management team and ensure that shareholders' interests are well served. Haw Par's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haw Par's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sat Khattar, Independent Director | ||
Siew Shiu, Acting Group Internal Audit Manager | ||
Meng Kwek, Regional General Manager of Underwater World Singapore Pte Ltd / Haw Par Leisure Pte Ltd | ||
Swee Sim, Non-Executive Independent Director | ||
Cho Wee, Non-Executive, Non Independent Chairman of the Board | ||
Chua Keeth, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
Wah Ng, Deputy General Manager-Manufacturing of Healthcare | ||
Ee Wee, CEO and President Director, Member of Investment Committee, CEO of Haw Par Healthcare Limited and Acting President of Haw Par Healthcare Limited | ||
Mui Kow, Senior Manager-Quality & Regulatory Affairs of Healthcare | ||
Brian Loo, Group Mang | ||
Peter Chew, Deputy General Manager of Underwater World Singapore Pte Ltd | ||
Kia Chew, Non-Executive Independent Director | ||
Choon Chew, Non-Executive Independent Director | ||
Tang Lee, Mang Communications | ||
Tang Chow, Human Director | ||
Anthony Chang, Curator of Underwater World Singapore Pte Ltd | ||
Suan Lee, Non-Executive Independent Director | ||
Kun Chiew, Group Sec | ||
Ah Han, Executive Director, Member of Investment Committee, General Manager of Haw Par Healthcare Limited and Director of Haw Par Healthcare Limited | ||
Hiang Gn, Non-Executive Independent Director | ||
Seok Lim, CFO and Company Secretary | ||
Sien Tarn, General Manager - Corporate Development & Property Division | ||
Sung Whang, General Manager of Underwater World Pattaya Ltd | ||
Soo Hwang, Non-Executive Independent Director | ||
Bee Goh, Director & General Manager - Manufacturing of Haw Par Healthcare Limited | ||
Say Chow, Group Finance Controller | ||
Jasmin Hong, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
Kay Lee, Company Secretary | ||
EeChao Wee, Non-Executive Deputy Chairman of the Board |
Haw Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Haw Par a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0424 | |||
Return On Asset | 0.0063 | |||
Profit Margin | 0.79 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | (701.58 M) | |||
Shares Outstanding | 221.37 M | |||
Shares Owned By Insiders | 36.98 % | |||
Shares Owned By Institutions | 32.30 % | |||
Price To Earning | 15.92 X | |||
Price To Book | 0.65 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haw Par. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Haw Pink Sheet analysis
When running Haw Par's price analysis, check to measure Haw Par's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haw Par is operating at the current time. Most of Haw Par's value examination focuses on studying past and present price action to predict the probability of Haw Par's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haw Par's price. Additionally, you may evaluate how the addition of Haw Par to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
CEOs Directory Screen CEOs from public companies around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |